CITATION REPORT List of articles citing

Tumour lysis syndrome: new therapeutic strategies and classification

DOI: 10.1111/j.1365-2141.2004.05094.x British Journal of Haematology, 2004, 127, 3-11.

Source: https://exaly.com/paper-pdf/36764188/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
709	One for the road! A study to assess the efficacy of single low-dose regimen of rasburicase in controlling hyperuricaemia in patients with tumour lysis syndrome due to haematological malignancies. 2013 , 7, 378		1
708	Continuing challenges in childhood non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2005 , 130, 480-8	4.5	19
707	Alterations in electrolyte equilibrium in patients with acute leukemia. 2005 , 75, 449-60		37
706	Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase. 2005 , 75, 518-21		30
705	[Acute renal failure]. 2005 , 46, 30-8		
704	Renal failure associated with cancer and its treatment: an update. 2005 , 16, 151-61		134
703	Pitfalls in predicting tumor lysis syndrome. 2006 , 47, 782-5		13
702	Unusual reaction to Rituximab with intra-vascular hemolysis, rhabdomyolysis, renal failure and bone marrow necrosis. 2006 , 47, 747-50		7
701	A predictive model for the detection of tumor lysis syndrome during AML induction therapy. 2006 , 47, 877-83		65
700	Postprocedure clinical management for the interventional radiologist. 2006 , 9, 106-12		6
699	UV-induced generation of rare tautomers of allopurinol and 9-methylhypoxanthine a matrix isolation FTIR study. 2006 , 122, 123-35		18
698	Abbreviated rasburicase dosing for the prevention and treatment of hyperuricemia in adults at risk for tumor lysis syndrome. 2006 , 3, 178-82		11
697	Oncologic emergencies: diagnosis and treatment. 2006 , 81, 835-48		64
696	Drug-associated renal dysfunction. 2006 , 22, 357-74, viii		95
695	Rasburicase: a review of its use in the management of anticancer therapy-induced hyperuricaemia. 2006 , 66, 529-45		28
694	Renal nucleoside transporters: physiological and clinical implications. 2006 , 84, 844-58		44
693	Clostridium spores as anti-tumour agents. 2006 , 14, 190-6		55

(2007-2006)

692	Multipolar radiofrequency ablation of large hepatic metastases of endocrine tumours. 2006 , 18, 89-92	17
691	Calcification of the gastric mucosa associated with tumor lysis syndrome in a child with non-Hodgkin lymphoma. 2006 , 28, 307-10	11
690	Tumour lysis syndrome in solid tumours. 2006 , 18, 773-80	97
689	Tumor lysis syndrome as a contributory factor to the development of reversible posterior leukoencephalopathy. 2006 , 48, 887-92	16
688	Treatment of Burkitt lymphoma in adults. 2006 , 6, 373-81	7
687	Multiple fiber laser-induced thermotherapy for ablation of large intrahepatic tumors. 2006 , 24, 3-9	20
686	The management of tumor lysis syndrome. 2006 , 3, 438-47	98
685	Tumour Lysis Syndrome Occurring in a Patient with Metastatic Gastrointestinal Stromal Tumour Treated with Glivec (Imatinib Mesylate, Gleevec, STI571). 2007 , 2007, 82012	13
684	Pegfilgrastim-induced hyperleukocytosis. 2007 , 41, 1524-30	11
683	Fatal spontaneous tumor lysis syndrome in a patient with metastatic, androgen-independent prostate cancer. 2007 , 100, 916-7	23
682	Intraoperative acute tumor lysis syndrome during laparoscopic splenectomy preceded by splenic artery embolization. 2007 , 17, 210-1	8
681	PEDIATRIC ONCOLOGY. 2007 , 25, 57-64	
680	Management of tumor lysis syndrome in adults. 2007 , 7, 233-9	19
679	Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout. 2007 , 4, 83-93	79
678	Features at presentation predict children with acute lymphoblastic leukemia at low risk for tumor lysis syndrome. 2007 , 110, 1832-9	33
677	Tumor lysis syndrome in elderly. 2007 , 64, 31-42	23
676	Tumour lysis syndrome with acute renal failure during imatinib therapy. 2007 , 31, 573-4	18
675	Tumour lysis syndrome developing during an operation. 2007 , 62, 85-7	23

674	Clarifying the role of rasburicase in tumor lysis syndrome. 2007 , 27, 111-21	19
673	A patient with hyperuricemia and renal failure:answer. 2007 , 22, 950-953	
672	Akuttherapie onkologischer Notfle. 2007 , 44, 74-87	1
671	Tumor lysis syndrome after treatment with gemcitabine for metastatic transitional cell carcinoma. 2007 , 24, 455-7	14
670	Acute tumor lysis syndrome after rituximab administration in Burkitt's lymphoma. 2008, 3, 161-3	9
669	Sevelamer hydrochloride: a novel treatment of hyperphosphatemia associated with tumor lysis syndrome in children. 2008 , 51, 59-61	13
668	Single dose rasburicase in tumor lysis: One hospital's experience. 2008 , 4, 18-20	3
667	Tumor lysis associated with dexamethasone use in a child with leukemia. 2008 , 18, 268-70	13
666	Tumor lysis syndrome during treatment with AMN107 (Nilotinib) in a patient with chronic myelogenous leukemia accelerated phase. 2008 , 33, 91-2	7
665	Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase. 2008 , 80, 331-6	50
664	A comparison of inpatient length of stay and costs among patients with hematologic malignancies (excluding hodgkin disease) associated with and without acute renal failure. 2008 , 8, 44-51	41
663	Farnesyl transferase inhibitors induce extended remissions in transgenic mice with mature B cell lymphomas. 2008 , 7, 39	5
662	Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. 2008 , 26, 2767-78	508
661	Acute tumor lysis syndrome during oral fludarabine treatment for chronic lymphocytic leukemia. Role of treatment with rasburicase. 2008 , 31, 197-9	8
660	Cetuximab-related tumor lysis syndrome in metastatic colon carcinoma. 2008 , 26, 2406-8	37
659	Massive uric acid nephrolithiasis with progressive renal failure due to spontaneous tumour lysis syndrome. 2008 , 1, 307-9	6
658	Rasburicase: future directions in tumor lysis management. 2008 , 8, 1595-604	18
657	Urate oxidase for prevention and treatment of tumor lysis syndrome in children with cancer. 2008,	2

(2010-2008)

656	Fatal acute tumor lysis syndrome following intrathecal chemotherapy for acute lymphoblastic leukemia with meningeal involvement. 2008 , 47, 1987-8	9
655	Uric acid: bystander or culprit in hypertension and progressive renal disease?. 2008 , 26, 2085-92	79
654	Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase). 2008 , 2, 129-41	18
653	Fatal Tumor Lysis Syndrome During Chemotherapy in Small Cell Lung Cancer. 2008 , 64, 215	
652	Acute spontaneous tumor lysis syndrome in a patient with squamous cell carcinoma of the lung. 2009 , 102, 71-3	21
651	Tumor lysis and acute renal failure in Burkitt's lymphoma: A review on pathophysiology and management. 2009 , 19, 83-6	6
650	Potent anti-tumor activity of systemically-administered IL2-expressing Salmonella correlates with decreased angiogenesis and enhanced tumor apoptosis. 2009 , 130, 89-97	64
649	Acute tumor lysis syndrome in a hemodialysis patient with diffuse large B cell lymphoma. 2009 , 26, 93-5	10
648	Complicated tumor lysis syndrome after CVVH treatment in a renal transplantation patient: One case report and literature review. 2009 , 6, 377-380	
647	Tumorlysesyndrom. 2009 , 4, 38-45	2
646	Tumorlysesyndrom. 2009, 4, 38-45 Efficacy of continuous venovenous hemofiltration with chemotherapy in patients with Burkitt lymphoma and leukemia at high risk of tumor lysis syndrome. 2009, 88, 639-45	2 23
	Efficacy of continuous venovenous hemofiltration with chemotherapy in patients with Burkitt	
646	Efficacy of continuous venovenous hemofiltration with chemotherapy in patients with Burkitt lymphoma and leukemia at high risk of tumor lysis syndrome. 2009 , 88, 639-45	23
646	Efficacy of continuous venovenous hemofiltration with chemotherapy in patients with Burkitt lymphoma and leukemia at high risk of tumor lysis syndrome. 2009 , 88, 639-45 Safety and efficacy of rasburicase (SR29142) in a Japanese phase II study. 2009 , 100, 357-62	23
646 645 644	Efficacy of continuous venovenous hemofiltration with chemotherapy in patients with Burkitt lymphoma and leukemia at high risk of tumor lysis syndrome. 2009 , 88, 639-45 Safety and efficacy of rasburicase (SR29142) in a Japanese phase II study. 2009 , 100, 357-62 Anesthesia for children with hyperleukocytosis a retrospective review. 2009 , 19, 1191-8	23 17 6
646 645 644	Efficacy of continuous venovenous hemofiltration with chemotherapy in patients with Burkitt lymphoma and leukemia at high risk of tumor lysis syndrome. 2009, 88, 639-45 Safety and efficacy of rasburicase (SR29142) in a Japanese phase II study. 2009, 100, 357-62 Anesthesia for children with hyperleukocytosis a retrospective review. 2009, 19, 1191-8 Management of pediatric tumor lysis syndrome in the emergency department. 2009, 27, 497-504	23 17 6
646 645 644 642	Efficacy of continuous venovenous hemofiltration with chemotherapy in patients with Burkitt lymphoma and leukemia at high risk of tumor lysis syndrome. 2009, 88, 639-45 Safety and efficacy of rasburicase (SR29142) in a Japanese phase II study. 2009, 100, 357-62 Anesthesia for children with hyperleukocytosis a retrospective review. 2009, 19, 1191-8 Management of pediatric tumor lysis syndrome in the emergency department. 2009, 27, 497-504 Anesthesia case of the month. Acute intraoperative tumor lysis. 2009, 234, 746-9 Transient spontaneous remission after tumor lysis syndrome triggered by a severe pulmonary	23 17 6 9

638	How to prevent and manage tumor lysis syndrome. 2010 , 40, 26-31; quiz 31-2		4
637	The tumor lysis syndrome in a child with multicentric Castleman disease. 2010 , 32, 247-9		4
636	4. Acute Kidney Injury caused by Blood Disease 2010 , 99, 957-963		
635	Supportive Care: Physical Consequences of Cancer and its Therapies. 2010 , 333-359		1
634	A patient with advanced hepatocellular carcinoma treated with sorafenib tosylate showed massive tumor lysis with avoidance of tumor lysis syndrome. 2010 , 49, 991-4		26
633	Maligne Erkrankungen und Nephropathie. 2010 , 5, 20-28		3
632	Tumor lysis syndrome and acute kidney injury: evaluation, prevention, and management. 2010 , 55, S1-13; quiz S14-9		73
631	Multicentric Castleman disease complicated by tumor lysis syndrome after systemic chemotherapy. 2010 , 34, e42-5		8
630	Tumour lysis syndrome after splenic irradiation in a patient with JAK2 V617F post-polycythaemia vera myelofibrosis. 2010 , 22, 893		3
629	Tumour lysis syndrome: an unusual presentation. 2010 , 65, 1031-3		4
629 628	Tumour lysis syndrome: an unusual presentation. 2010 , 65, 1031-3 Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. <i>British Journal of Haematology</i> , 2010 , 149, 578-86	4.5	337
	Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. <i>British Journal of</i>	4.5	
	Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. <i>British Journal of Haematology</i> , 2010 , 149, 578-86	4.5	337
628 627	Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. <i>British Journal of Haematology</i> , 2010 , 149, 578-86 Self-sufficient control of urate homeostasis in mice by a synthetic circuit. 2010 , 28, 355-60	4.5	337
628 627 626	Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. <i>British Journal of Haematology</i> , 2010 , 149, 578-86 Self-sufficient control of urate homeostasis in mice by a synthetic circuit. 2010 , 28, 355-60 Live Clostridia: A Powerful Tool in Tumor Biotherapy. 2010 , 71-97 Severe Spontaneous Acute Tumor Lysis Syndrome and Hypoglycemia in Patient with Germ Cell	4.5	337 202 2
628 627 626	Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. <i>British Journal of Haematology</i> , 2010 , 149, 578-86 Self-sufficient control of urate homeostasis in mice by a synthetic circuit. 2010 , 28, 355-60 Live Clostridia: A Powerful Tool in Tumor Biotherapy. 2010 , 71-97 Severe Spontaneous Acute Tumor Lysis Syndrome and Hypoglycemia in Patient with Germ Cell Tumor. 2010 , 96, 1040-1043 Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol aloneresults	4.5	337 202 2
628 627 626 625	Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. <i>British Journal of Haematology</i> , 2010 , 149, 578-86 Self-sufficient control of urate homeostasis in mice by a synthetic circuit. 2010 , 28, 355-60 Live Clostridia: A Powerful Tool in Tumor Biotherapy. 2010 , 71-97 Severe Spontaneous Acute Tumor Lysis Syndrome and Hypoglycemia in Patient with Germ Cell Tumor. 2010 , 96, 1040-1043 Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol aloneresults of a multicenter phase III study. 2010 , 28, 4207-13	4.5	337 202 2 13

(2011-2010)

620	Hyperkalemia complicating propranolol treatment of an infantile hemangioma. 2010 , 126, e1589-93	78
619	Spontaneous tumor lysis syndrome in the setting of B-cell lymphoma. 2010 , 2010, 610969	8
618	Acute kidney injury in critically ill patients with cancer. 2010 , 26, 151-79	39
617	Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer. 2010 , CD006945	17
616	Electrolyte disturbances and acute kidney injury in patients with cancer. 2010 , 30, 534-47	32
615	Life-threatening hyperkalemia during radiofrequency ablation of hepatocellular carcinoma. 2010 , 22, 473-6	3
614	An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome. 2010 , 36, 164-76	60
613	Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome. 2010 , 16, 205-13	13
612	Oncologic emergencies. 2010 , 26, 181-205	50
611	CEho prevenir y tratar el : sEldrome de lisis tumoral. 2010 , 28, 8-13	
610	Cfho prevenir y tratar el : sfidrome de lisis tumoral. 2010 , 28, 8-13 Prognostic significance of acute renal injury in acute tumor lysis syndrome. 2010 , 51, 221-7	65
		65 4
610	Prognostic significance of acute renal injury in acute tumor lysis syndrome. 2010 , 51, 221-7	
610	Prognostic significance of acute renal injury in acute tumor lysis syndrome. 2010 , 51, 221-7 Treatment of tumor lysis syndrome with the highest known uric acid level. 2010 , 32, 895-8	4
610 609 608	Prognostic significance of acute renal injury in acute tumor lysis syndrome. 2010 , 51, 221-7 Treatment of tumor lysis syndrome with the highest known uric acid level. 2010 , 32, 895-8 Tumor lysis syndrome in intensive therapy: diagnostic and therapeutic encare. 2011 , 35, 170-178	1
610 609 608	Prognostic significance of acute renal injury in acute tumor lysis syndrome. 2010, 51, 221-7 Treatment of tumor lysis syndrome with the highest known uric acid level. 2010, 32, 895-8 Tumor lysis syndrome in intensive therapy: diagnostic and therapeutic encare. 2011, 35, 170-178 The tumor lysis syndrome. 2011, 364, 1844-54 Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic	4 1 633
610 609 608 607	Prognostic significance of acute renal injury in acute tumor lysis syndrome. 2010, 51, 221-7 Treatment of tumor lysis syndrome with the highest known uric acid level. 2010, 32, 895-8 Tumor lysis syndrome in intensive therapy: diagnostic and therapeutic encare. 2011, 35, 170-178 The tumor lysis syndrome. 2011, 364, 1844-54 Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients. 2011, 22, 2073-2079	4 1 633 49

602 Nefropat obstructiva y por reflujo. **2011**, 10, 5490-5500

601	Hematology and Oncology Problems in the Intensive Care Unit. 2011 , 1151-1161	
600	Emerging role of rasburicase in the management of increased plasma uric acid levels in patients with hematologic malignancies. 2011 , 2, 1-6	7
599	[IV. Others: 6. Malignancy and kidney injury]. 2011 , 100, 1330-5	1
598	[108th Scientific Meeting of the Japanese Society of Internal Medicine: symposium: 3. The interaction between kidney and other organs; What should physicians know about it? (4) Hematological disorders and kidney involvement]. 2011 , 100, 2552-8	
597	A case of tumor lysis syndrome following chemotherapy for a uterine epithelioid leiomyosarcoma with focal rhabdomyosarcomatous differentiation. 2011 , 37, 947-52	9
596	A review of tumour lysis syndrome with targeted therapies and the role of rasburicase. 2011 , 36, 299-326	25
595	Management of tumour lysis syndrome in children: what is the evidence for prophylactic rasburicase in non-hyperleucocytic leukaemia?. <i>British Journal of Haematology</i> , 2011 , 153, 275-7	7
594	The clinical management of tumour lysis syndrome in haematological malignancies. <i>British Journal of Haematology</i> , 2011 , 154, 3-13	44
593	[Tumor lysis syndrome in intensive therapy: diagnostic and therapeutic encare]. 2011, 35, 170-8	8
592	Renal Disease in Hematological Malignancies. 2011 , 13, 5-18	
591	Oncologic emergencies: Pathophysiology, presentation, diagnosis, and treatment. 2011 , 61, 287-314	57
590	Metabolic Emergencies in the Child With Acute Leukemia. 2011 , 12, 191-201	1
589	Management of common oncologic emergencies. 2011 , 78, 709-17	13
588	Risk evaluation, prophylaxis, and treatment of tumor lysis syndrome: consensus of an Italian expert panel. 2011 , 28, 684-97	14
587	Tumour lysis syndrome in children: experience of last decade. 2011 , 29, 196-201	11
586	Compact optical microfluidic uric acid analysis system. 2011 , 26, 4155-61	4
585	Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies. 2011 , 46, 800-5	45

(2012-2011)

584	Tumor lysis syndrome and acquired ichthyosis occurring after chemotherapy for lung adenocarcinoma. 2011 , 29, e859-60	7
583	The tumor lysis syndrome. 2011 , 365, 573; author reply 573-4	11
582	Pediatric non-Hodgkin lymphoma: a retrospective 14-year experience with Berlin-Frankfurt-Mfister (BFM) protocols from a tertiary care hospital in Serbia. 2012 , 29, 109-18	5
581	Hyperuricemic renal failure in nonhematologic solid tumors: a case report and review of the literature. 2012 , 2012, 314056	10
580	An unusual presentation of tumor lysis syndrome in a patient with advanced gastric adenocarcinoma: case report and literature review. 2012 , 2012, 468452	31
579	Spontaneous tumour lysis syndrome. 2012 , 184, 913-6	45
578	Extracorporeal life support in the acute management of tumour lysis syndrome. 2012 , 15, 568-9	11
577	Rasburicase for the treatment of tumor lysis in hematological malignancies. 2012 , 5, 27-38	11
576	A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. 2012 , 23, 1640-5	66
575	Tumor lysis syndrome: a systematic review of case series and case reports. 2012 , 124, 92-101	29
574	Acute disseminated intravascular coagulation in neuroendocrine carcinoma. 2012 , 5, 524-9	7
573	Unprecedented case of tumor lysis syndrome in a patient with metastatic pancreatic adenocarcinoma. 2012 , 41, 659-61	7
572	Early mortality in children with advanced mature B-cell malignancies in a middle-income country. 2012 , 34, e266-70	10
571	Oncologic emergencies. 2012 , 40, 2212-22	94
570	Diagnosis and treatment of rituximab-induced acute tumor lysis syndrome in patients with diffuse large B-cell lymphoma. 2012 , 343, 337-41	16
569	How I treat hematologic emergencies in adults with acute leukemia. 2012 , 120, 1993-2002	48
568	[Therapeutic of respiratory manifestations at the early phase of acute myeloid leukaemia]. 2012 , 29, 743-55	3
567	Chronic lymphocytic leukemia associated with immunotactoid glomerulopathy: a case report of successful treatment with high-dose methylprednisolone in combination with rituximab followed by alemtuzumab. 2012 , 53, 1835-8	8

566	Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. 2012 , 53, 417-23		51
565	Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies. 2012 , 5, 75		54
564	Hematology and Oncology in Critical Illness. 2012 , 801-850		2
563	Onco-nephrology: tumor lysis syndrome. 2012 , 7, 1730-9		91
562	Managing adverse events associated with chemotherapy and immunotherapy for follicular lymphoma. 2012 , 9, S68-S76		
561	Therapeutic synthetic gene networks. 2012 , 23, 703-11		24
560	Tumour Lysis Syndrome: a Rare Complication of Trans-Arterial Chemo-Embolisation with Doxorubicin Beads for Hepatocellular Carcinoma. 2012 , 43 Suppl 1, S187-90		6
559	Bendamustine for treatment of chronic lymphocytic leukemia. 2012 , 13, 1495-505		11
558	Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia. <i>British Journal of Haematology</i> , 2012 , 156, 730-43	4.5	58
557	Subclinical tumor lysis-like syndrome during treatment of visceral leishmaniasis with low-dose intermittent liposomal amphotericin B. 2012 , 7, 305-309		1
556	Methemoglobinemia and hemolysis in a patient with G6PD deficiency treated with rasburicase. 2013 , 88, 152-4		48
555	Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis. 2013 , 62, 481-	92	52
554	Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en R\(\text{B}\)nimation Respiratoire et Onco-H\(\text{Thatologique}\). British Journal of Haematology, 2013 , 162, 489-97	4.5	63
553	Tumor lysis syndrome: authors' reply. 2013 , 80, 979		
552	Tumor lysis syndrome soon after treatment with hydroxyurea followed by nilotinib in two patients with chronic-phase chronic myelogenous leukemia. 2013 , 98, 243-6		7
551	Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias. 2013 , 72, 897-908		55
550	Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children's Oncology Group Report. <i>British Journal of Haematology</i> , 2013 , 163, 365-72	4.5	38
549	Premier cas de syndrome de lyse tumorale peropfatoire chez un enfant, rMateur dun lymphome B EBV+ avec hyperkalifhie maligne fatale. 2013 , 9, 350		

548	Tumor lysis syndrome. 2013 , 80, 50-4	10
547	Anaesthetic management of the child with haematological malignancy. 2013 , 13, 158-164	2
546	Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis. 2013 , 38, 301-8	38
545	Therapeutic Approaches to Burkitt Lymphoma. 2013 , 251-268	1
544	Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome. 2013 , 33, 295-303	31
543	Specific Etiologies. 2013 , 199-236	
542	Clinical Implications of Burkitt Lymphoma. 2013 , 67-80	
541	Tumour lysis syndrome. 2013 , 74 Suppl 12, C178-81	
540	Oncologic Emergencies (Including Hypercalcemia). 2013 , 404-409	
539	Mortality following rasburicase-induced methemoglobinemia. 2013 , 47, 1353-8	21
539 538	Mortality following rasburicase-induced methemoglobinemia. 2013, 47, 1353-8 Early morbidity and mortality in childhood acute lymphoblastic leukemia with very high white blood cell count. 2013, 27, 2259-62	6
	Early morbidity and mortality in childhood acute lymphoblastic leukemia with very high white blood	
538	Early morbidity and mortality in childhood acute lymphoblastic leukemia with very high white blood cell count. 2013 , 27, 2259-62 Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after	6
538 537	Early morbidity and mortality in childhood acute lymphoblastic leukemia with very high white blood cell count. 2013 , 27, 2259-62 Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. 2013 , 31, 3688-95	6 269
538537536	Early morbidity and mortality in childhood acute lymphoblastic leukemia with very high white blood cell count. 2013, 27, 2259-62 Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. 2013, 31, 3688-95 Tumor lysis syndrome in limited-stage small-cell lung cancer. 2013, 8, e61-2 Gemcitabine and cisplatin-induced tumor lysis syndrome in a patient with gallbladder carcinoma: A	6 269 2
538537536535	Early morbidity and mortality in childhood acute lymphoblastic leukemia with very high white blood cell count. 2013, 27, 2259-62 Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. 2013, 31, 3688-95 Tumor lysis syndrome in limited-stage small-cell lung cancer. 2013, 8, e61-2 Gemcitabine and cisplatin-induced tumor lysis syndrome in a patient with gallbladder carcinoma: A case report. 2013, 5, 1237-1239	6 269 2
538537536535534	Early morbidity and mortality in childhood acute lymphoblastic leukemia with very high white blood cell count. 2013, 27, 2259-62 Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. 2013, 31, 3688-95 Tumor lysis syndrome in limited-stage small-cell lung cancer. 2013, 8, e61-2 Gemcitabine and cisplatin-induced tumor lysis syndrome in a patient with gallbladder carcinoma: A case report. 2013, 5, 1237-1239 Spontaneous Tumor Lysis Syndrome in Childhood T cell Acute Lymphoblastic Leukemia. 2013, 28, e063	6 269 2 4

530	Tumor Lysis Syndrome in Solid Tumors: An up to Date Review of the Literature. 2014 , 6, 5389	107
529	Tumor lysis syndrome in multiple myeloma treated with bortezomib. 2014 , 5, 161-2	4
528	Tumor lysis syndrome and acute anemia in an African-American man with chronic lymphocytic leukemia. 2014 , 2014, 138-40	5
527	Hyperuricemia in hematologic malignancies is caused by an insufficient urinary excretion. 2014 , 33, 434-8	5
526	Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer. 2014 , CD006945	11
525	Carfilzomib-associated tumor lysis syndrome. 2014 , 34, e34-7	15
524	Plasma uric acid response to rasburicase: early marker for acute kidney injury in tumor lysis syndrome?. 2014 , 55, 2362-7	11
523	Tumor lysis syndrome: risk factors, diagnosis, and management. 2014 , 30, 571-6; quiz 577-9	14
522	Tumor Lysis Syndrome. 2014 , 39-64	4
521	Use of rasburicase in a pregnant woman with acute lymphoblastic leukaemia and imminent tumour lysis syndrome. 2014 , 93, 531-2	3
520	Viral lymphomagenesis: from pathophysiology to the rationale for novel therapies. <i>British Journal of Haematology</i> , 2014 , 165, 300-15	15
519	Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells. 2014 , 343, 172-8	104
518	Tumor lysis syndrome: new challenges and recent advances. 2014 , 21, 18-26	114
517	Factors associated with acute kidney injury in children receiving vancomycin. 2014 , 48, 1555-62	43
516	Solution structures of purine base analogues 6-chloroguanine, 8-azaguanine and allopurinol. 2014 , 32, 27-35	5
515	Rapid progression of anemia related to tumor-lysis syndrome associated with bortezomib treatment in myeloma patients. 2014 , 44, 435-41	4
514	Complications of "very high" leukocytosis in pediatric acute leukemia patients managed without rasburicase and leukopheresis. 2014 , 81, 817-20	1
513	Haematological Emergencies. 2014, 233-242	

512	Transarterial Chemoembolization-induced Tumor Lysis Syndrome: Different Results in the Same Hepatocellular Carcinoma Patient. 2014 , 8, 171-174	2
511	Les leucfhies aigul lymphoblastiques conglitales : explience franllise entre 1990 et 2010. 2014 , 2, 7-14	
510	Acute kidney injury in the cancer patient. 2014 , 21, 64-71	41
509	Oncologic metabolic emergencies. 2014 , 32, 509-25	12
508	Spontaneous tumor lysis syndrome in renal cell carcinoma: a case report. 2014 , 12, e225-7	11
507	Acute renal failure and type B lactic acidosis as first manifestation of extranodal T-cell lymphoblastic lymphoma. 2014 , 2014,	2
506	Controlling serum uric acid using febuxostat in cancer patients at risk of tumor lysis syndrome. 2014 , 8, 1523-1527	11
505	Ibrutinib-associated tumor lysis syndrome in a patient with chronic lymphocytic leukemia. 2014 , 124, 3503-5	19
504	Tumor Lysis Syndrome in a Retroperitoneal Sarcoma. 2014 , 2, 2324709614542340	2
503	Severe hyperuricemia with acute kidney injury: Vigilance needed for spontaneous tumor lysis syndrome. 2015 , 4, 41-43	1
502	Diagnostic pitfalls of discriminating lymphoma-associated effusions. 2015 , 94, e800	3
501	Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. 2015 , 126, 739-45	268
500	Reduced administration of rasburicase for tumor lysis syndrome: A single-institution experience. 2015 , 9, 2119-2125	O
499	Hypersensitivity and tumor lysis syndrome associated with cetuximab treatment: should we be afraid?. 2015 , 101, e40-5	1
498	What is your diagnosis? Urine crystals in a dog. 2015 , 44, 613-4	3
497	Rasburicase-induced methemoglobinemia in two African-American female patients: an under-recognized and continued problem. 2015 , 94, 83-5	16
496	Rasburicase-Induced Methemoglobinemia in a Patient with Aggressive Non-Hodgkin's Lymphoma. 2015 , 16, 590-3	8
495	Tumor lysis syndrome in the emergency department: challenges and solutions. 2015 , 7, 39-44	5

494	Uric acid and the prediction models of tumor lysis syndrome in AML. 2015 , 10, e0119497	15
493	A Case of Spontaneous Tumor Lysis Syndrome in a Patient with Ovarian Cancer. 2015 , 2015, 461870	16
492	A tumour lysis syndrome in a chemotherapy naMe patient with metastatic pancreatic adenocarcinoma. 2015 , 2015,	12
491	Kidney diseases associated with haematological cancers. 2015 , 11, 478-90	13
490	Oncologic emergencies in critical care. 2015 , 167-200	
489	Supportive medical care for children with acute lymphoblastic leukemia in low- and middle-income countries. 2015 , 8, 613-26	10
488	Rasburicase in the management of tumor lysis: an evidence-based review of its place in therapy. 2015 , 10, 23-38	21
487	Spontaneous Tumor Lysis Syndrome: A Case Report and Critical Evaluation of Current Diagnostic Criteria and Optimal Treatment Regimens. 2015 , 3, 2324709615603199	20
486	Effect of the duration between total body irradiation and stem cell infusion on the outcome of allogeneic transplantation with myeloablative conditioning. 2015 , 20, 410-5	1
485	Risk of anaphylaxis with repeated courses of rasburicase: a Research on Adverse Drug Events and Reports (RADAR) project. 2015 , 38, 183-7	34
484	Tumor lysis syndrome after treatment with sorafenib for hepatocellular carcinoma. 2015 , 4, 147-150	3
483	Spontaneous tumour lysis syndrome with follicular lymphoma. 2015 , 76, 172-3	
482	FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. 2015 , 26, 2155-61	44
481	Tumor lysis syndrome: A clinical review. 2015 , 4, 130-8	75
480	Management of tumor lysis syndrome in patients with multiple myeloma during bortezomib treatment. 2015 , 19, E4-7	7
479	Tumor lysis syndrome and primary hepatic malignancy: case presentation and review of the literature. 2015 , 32, 3-9	5
478	Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia. 2015 , 39, 495-500	41
477	Entanglement of sepsis, chronic kidney disease, and other comorbidities in patients who develop acute kidney injury. 2015 , 35, 23-37	10

476	Onco-nephrology: current concepts and future perspectives. 2015 , 45, 617-28		21
475	Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. <i>British Journal of Haematology</i> , 2015 , 169, 661-71	4.5	97
474	Effective Prevention and Management of Tumor Lysis Syndrome in Children With Cancer: The Important Contributions of Pediatric Oncology Nurses. 2015 , 32, 209-18		2
473	Risk factors for tumor lysis syndrome in childhood acute myeloid leukemia treated with a uniform protocol without rasburicase prophylaxis. 2015 , 56, 2193-5		2
472	Medical management of tumor lysis syndrome, postprocedural pain, and venous thromboembolism following interventional radiology procedures. 2015 , 32, 209-16		3
471	A focused review of the pathogenesis, diagnosis, and management of tumor lysis syndrome for the interventional radiologist. 2015 , 32, 231-6		4
470	50-Year-Old Man With New-Onset Acute Kidney Injury. 2015 , 90, 1420-3		1
469	Electrolyte Disorders in Cancer Patients. 2015 , 131-162		7
468	Tumor Lysis Syndrome. 2015 , 163-181		2
467	Acute kidney injury in adults with hemophagocytic lymphohistiocytosis. 2015 , 65, 851-9		52
466	Supportive care in pediatric oncology: oncologic emergencies and management of fever and neutropenia. 2015 , 62, 27-46		18
465	Low-dose rasburicase in hematologic malignancies. 2015 , 82, 458-61		7
464	Management of Acute Myeloid Leukemia in the Intensive Care Setting. 2015, 30, 375-84		5
463	Spontaneous tumour lysis syndrome secondary to the transformation of chronic myelomonocytic leukaemia into acute myeloid leukaemia. 2016 , 2016,		2
462	Spontaneous Tumour Lysis Syndrome in a Multiple Myeloma. 2016 , 2016, 9620520		3
461	Preventing Tumor Lysis Syndrome: Two Case Studies of Unexpected Outcomes. 2016 , 20, 195-200		5
460	Severe Tumor Lysis Syndrome in a Patient With Pancreatic Adenocarcinoma. 2016 , 45, e12-3		3
459	Oncologic emergencies. 2016 , 321-350		

458	The Role of Leukapheresis in the Current Management of Hyperleukocytosis in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia. 2016 , 63, 1546-51	19
457	Tumor Lysis-like Syndrome in Eosinophilic Disease of the Lung: A Case Report and Review of the Literature. 2016 , 55, 3029-3034	Ο
456	Spontaneous tumor lysis syndrome in the setting of small cell lung cancer: Report of two cases and review of the literature. 2016 , 9, 92-95	4
455	An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells. 2016 , 59, 379-85	12
454	Tumour lysis syndrome: A rare acute presentation of locally advanced testicular cancer - Case report and review of literature. 2016 , 3, 49-52	1
453	Acute tumor lysis syndrome after proximal splenic artery embolization. 2016 , 11, 90-2	6
452	Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial. 2016 , 57, 1291-9	16
451	Tumor Lysis Syndrome: A Serious Complication of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma. 2016 , 129, e173-6	6
450	Serum Uric Acid Exhibits Inverse Relationship with Estimated Glomerular Filtration Rate. 2016 , 134, 231-237	13
449	Tumor Lysis Syndrome. 2016 , 5, 425-438	
449 448	Tumor Lysis Syndrome. 2016 , 5, 425-438 Utilizing intein-mediated protein cleaving for purification of uricase, a multimeric enzyme. 2016 , 93-94, 92-98	8
	Utilizing intein-mediated protein cleaving for purification of uricase, a multimeric enzyme. 2016 ,	8
448	Utilizing intein-mediated protein cleaving for purification of uricase, a multimeric enzyme. 2016 , 93-94, 92-98 Investigating Effects of Acidic pH on Proliferation, Invasion and Drug-Induced Apoptosis in	
448	Utilizing intein-mediated protein cleaving for purification of uricase, a multimeric enzyme. 2016 , 93-94, 92-98 Investigating Effects of Acidic pH on Proliferation, Invasion and Drug-Induced Apoptosis in Lymphoblastic Leukemia. 2016 , 9, 119-126 Rasburicase-induced methemoglobinemia: case report, literature review, and proposed treatment	16
448 447 446	Utilizing intein-mediated protein cleaving for purification of uricase, a multimeric enzyme. 2016, 93-94, 92-98 Investigating Effects of Acidic pH on Proliferation, Invasion and Drug-Induced Apoptosis in Lymphoblastic Leukemia. 2016, 9, 119-126 Rasburicase-induced methemoglobinemia: case report, literature review, and proposed treatment algorithm. 2016, 4, 315-9	16
448 447 446 445	Utilizing intein-mediated protein cleaving for purification of uricase, a multimeric enzyme. 2016, 93-94, 92-98 Investigating Effects of Acidic pH on Proliferation, Invasion and Drug-Induced Apoptosis in Lymphoblastic Leukemia. 2016, 9, 119-126 Rasburicase-induced methemoglobinemia: case report, literature review, and proposed treatment algorithm. 2016, 4, 315-9 Bulky Solid Tumors in Elderly Adults: Beware of Spontaneous Tumor Lysis Syndrome. 2016, 64, 235-7	16 16 6
448 447 446 445 444	Utilizing intein-mediated protein cleaving for purification of uricase, a multimeric enzyme. 2016, 93-94, 92-98 Investigating Effects of Acidic pH on Proliferation, Invasion and Drug-Induced Apoptosis in Lymphoblastic Leukemia. 2016, 9, 119-126 Rasburicase-induced methemoglobinemia: case report, literature review, and proposed treatment algorithm. 2016, 4, 315-9 Bulky Solid Tumors in Elderly Adults: Beware of Spontaneous Tumor Lysis Syndrome. 2016, 64, 235-7 Tumor lysis syndrome in anti-androgen-treated metastatic prostate cancer. 2016, 48, 1837-1838	16 16 6

440	Das Tumorlysesyndrom. 2016 , 11, 6-13	1
439	Tumor lysis syndrome following trastuzumab and pertuzumab for metastatic breast cancer: a case report. 2016 , 10, 178	6
438	Sevelamer is an Effective Drug in Treating Hyperphosphatemia Due to Tumor Lysis Syndrome in Children: A Developing World Experience. 2016 , 32, 78-82	3
437	Tumor lysis syndrome: review of pathogenesis, risk factors and management of a medical emergency. 2016 , 9, 197-208	24
436	Oncologic Emergencies. 2016 , 1, 397-408	
435	Management of Carfilzomib-Associated Cardiac Adverse Events. 2016 , 16, 241-5	33
434	[Mineral-based alkaline waters' prescription in France: Patients are the key point for both nephrologists and urologists]. 2016 , 12, 38-47	O
433	Tumor Lysis Syndrome in an Unusual Metastatic Pancreatic Neuroendocrine Tumor with Ectopic ACTH Secretion. 2016 , 47, 423-428	
432	A review in the treatment of oncologic emergencies. 2016 , 22, 625-38	22
431	Ibrutinib-associated tumor lysis syndrome in a patient with mantle cell lymphoma: A case report. 2017 , 23, 235-239	4
430	Impact of dialysis requirement on outcomes in tumor lysis syndrome. 2017 , 22, 85-88	14
429	Tumor lysis syndrome in solid tumors: Clinical characteristics and prognosis. 2017 , 148, 121-124	12
428	Efficacy and safety of dinaciclib vs ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia. 2017 , 129, 1876-1878	43
427	Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer. 2017 , 3, CD006945	6
426	Tumor Lysis Syndrome: A Unique Solute Disturbance. 2017 , 52, 309-320	6
425	Spontaneous tumour lysis syndrome in cervical cancer. 2017 , 37, 679-680	О
424	Oncologic Emergencies. 2017 , 1-21	2
423	Severe Case of Tumor Lysis Syndrome Presenting Spontaneously in a Metastatic Pancreatic Adenocarcinoma Patient. 2017 , 46, e31-e32	3

Analyse et critique des recommandations britanniques 2015 de prise en charge du syndrome de lyse tumorale de l\(\extrm{d}\) dulte. **2017**, 26, 285

421	Emergencies in Hematology and Oncology. 2017 , 92, 609-641	19
420	A rare seizure: Tumor lysis syndrome after radiation therapy of a solid tumor. 2017 , 35, 941.e3-941.e4	4
419	Tumour lysis syndrome in solid tumors: Clinical characteristics and prognosis. 2017 , 148, 121-124	1
418	Spontaneous tumor lysis syndrome in a patient with metastatic prostate cancer. 2017, 6, 589-592	9
417	Tumor lysis syndrome in an extraskeletal osteosarcoma: a case report and review of the literature. 2017 , 11, 79	4
416	A Clinical and Economic Comparison of Rasburicase and Allopurinol in the Treatment of Patients With Clinical or Laboratory Tumor Lysis Syndrome. 2017 , 17, 173-178	20
415	Treatment of Oncological Emergencies. 2017 , 6, 283-294	
414	Oncologic Metabolic Emergencies. 2017 , 31, 941-957	12
413	Spontaneous tumor lysis syndrome occurring in untreated uterine cancer. 2017 , 22, 40-42	3
412	Variable Potassium Concentrations: Which Is Right and Which Is Wrong?. 2017 , 48, 183-187	4
411	Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents. 2017 , 22, 1283-1291	39
410	A phase 1 study of the Janus kinase 2 (JAK2) inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia. 2017 , 61, 89-95	24
409	Effectiveness of Single-dose Rasburicase in Patients With Lymphoid Malignancies at a High Risk for Tumor Lysis Syndrome. 2017 , 17, 595-603	1
408	Spontaneous tumor lysis syndrome in colon cancer: a case report and literature review. 2017 , 5, 2121-2126	14
407	Oncologic Emergencies. 2017 , 393-408	
406	Tumor lysis syndrome in a patient with ovarian yolk sac tumor. 2017 , 22, 92-93	1
405	Spontaneous tumour lysis syndrome in hepatocellular carcinoma presenting with hypocalcemic tetany: An unusual case and systematic literature review. 2017 , 41, e29-e31	5

404	Non-Hodgkin Lymphoma. 2017 , 69-117	1
403	[Analysis of the 2015 British guidelines on the prevention and management of tumor lysis syndrome]. 2017 , 38, 36-43	3
402	The experience of a sudden death by acute tumor lysis syndrome in oral cancer patient with liver metastasis. 2017 , 29, 78-83	1
401	Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase. 2017 , 10, 597-605	48
400	Tumor Lysis Syndrome in Patients with Hematological Malignancies. 2017 , 2017, 9684909	39
399	Spontaneous Tumor Lysis Syndrome due to Uterine Leiomyosarcoma with Lung Metastases. 2017 , 2017, 4141287	4
398	Bortezomib treatment induces a higher mortality rate in lupus model mice with a higher disease activity. 2017 , 19, 187	7
397	Rasburicase-induced Hemolytic Anemia in an Adolescent With Unknown Glucose-6-Phosphate Dehydrogenase Deficiency. 2017 , 22, 471-475	3
396	Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. 2017 , 35, 826-833	442
395	Pazopanib-related tumor lysis syndrome in metastatic clear cell renal cell carcinoma: a case report. 2018 , 36, 513-516	2
394	Fatal cardiac arrhythmia caused by tumor lysis in a patient with diffuse large B-cell lymphoma upon start of R-CHOP. 2018 , 6, 490-493	1
393	Tumor lysis syndrome associated with docetaxel and carboplatin in a case with recurrent endometrial cancer. 2018 , 24, 21-23	4
392	Efficacy of Single Dose Rasburicase (1.5 mg) for Prophylaxis and Management of Laboratory Tumor Lysis Syndrome. 2018 , 34, 618-622	4
391	Spontaneous tumor lysis syndrome in small cell lung cancer. 2018 , 31, 79-80	4
390	From skin to spontaneous lysis: A case of spontaneous tumor lysis syndrome in metastatic melanoma. 2018 , 24, 221-225	5
389	Acute kidney injury in critically ill patients with solid tumours. 2018 , 33, 1997-2005	19
388	Single dose Rasburicase is a clinically effective pharmacoeconomic approach for preventing tumour lysis syndrome in children with high tumour burden. <i>British Journal of Haematology</i> , 2018 , 181, 696-698 $^{4.5}$	4
387	Rational use of rasburicase for the treatment and management of tumor lysis syndrome. 2018 , 24, 176-184	5

386	The effect of therapeutic leukapheresis on early complications and outcomes in patients with acute leukemia and hyperleukocytosis: a propensity score-matched study. 2018 , 58, 208-216	23
385	Guidelines for treatment of renal injury during cancer chemotherapy 2016. 2018 , 22, 210-244	37
384	Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study. 2018 , 25, 108-117	4
383	Spontaneous tumor lysis syndrome in a patient with newly diagnosed metastatic colonic adenocarcinoma. 2018 , 20, S41-S43	4
382	[Metabolic disorders as paraneoplastic syndromes]. 2018 , 59, 114-124	0
381	[Bicarbonate: From physiology to treatment for all clinicians]. 2018 , 14, 13-23	O
380	Tumour lysis syndrome: a rare side effect of imatinib therapy for GIST. 2018, 11,	1
379	Spanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, treatment, and follow-up of diffuse large B-cell lymphoma. 2018 , 9, 32383-32399	6
378	Cytokine release syndrome. 2018 , 4, 134-141	9
377	Tubulointerstitial and intraglomerular metastasis with subsequent development of tumor lysis syndrome in a patient with advanced metastatic melanoma. 2018 , 2, 24-30	2
376	Evaluation and characterization of tumor lysis syndrome before and after chemotherapy among pediatric oncology patients in Tikur Anbessa specialized hospital, Addis Ababa, Ethiopia. 2018 , 18, 22	4
375	Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL. 2018 , 2, 3566-3571	16
374	64-Year-Old Woman With General Malaise and Hypercalcemia. 2018 , 93, 1144-1148	1
373	A hypothetical method for controlling highly glycolytic cancers and metastases. 2018 , 118, 19-25	3
372	Venetoclax: Targeting BCL2 in Hematological Cancers. 2018 , 212, 215-242	13
371	The Warburg Effect as a Type B Lactic Acidosis in a Patient With Acute Myeloid Leukemia: A Diagnostic Challenge for Clinicians. 2018 , 8, 232	11
370	Rapid Fire: Tumor Lysis Syndrome. 2018 , 36, 517-525	7
369	Successful treatment of a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia complicated by bone marrow necrosis and acute renal insufficiency: A case report. 2018 , 9, 297-301	O

368	Risk-based management strategy and outcomes of tumor lysis syndrome in children with leukemia/lymphoma: Analysis from a resource-limited setting. 2018 , 65, e27401	6
367	Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. 2018 , 19, 1215-1228	70
366	Comparison of fixed versus traditional weight-based dosing of rasburicase in a pediatric population. 2018 , 65, e27236	6
365	Impact of daytime continuous veno-venous haemofiltration on treatment of paediatric tumour lysis syndrome. 2018 , 46, 3613-3620	2
364	Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia. 2019 , 104, 147-154	7
363	Recent advances in ultra-small fluorescent Au nanoclusters toward oncological research. 2019 , 11, 17967-179	98 98
362	Tumor lysis syndrome following cabazitaxel administration for metastatic castration-resistant prostate cancer: A case report. 2019 , 2, 179-182	1
361	Editorial Comment to Tumor lysis syndrome following cabazitaxel administration for metastatic castration-resistant prostate cancer: A case report. 2019 , 2, 183	
360	Malnutrition, Sepsis, and Tumor Lysis Syndrome Are Associated with Increased Rate of Acute Mortality in Mature B Cell Non-Hodgkin Lymphoma in a Pediatric Population-Study from Tertiary Care Hospital in Pakistan. 2019 , 11, e2019043	1
359	How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. 2019 , 33, 2795-2804	67
358	Current understanding of tumor lysis syndrome. 2019 , 37, 537-547	23
357	Myocardial calcification in a patient with B-lymphoblastic leukemia accompanied by tumor lysis syndrome. 2019 , 43, 107146	2
356	Tumor Lysis Syndrome: A Practical Guide for Nurse Practitioners. 2019 , 15, 636-639	1
355	Bone marrow metastasis of small cell lung carcinoma with spontaneous tumor lysis syndrome without hepatic metastasis at diagnosis: first case report in Korea and review of literature. 2019 , 54, 231-233	1
354	Understanding tumor lysis syndrome. 2019 , 45, 1608-1611	6
353	Spontaneous tumor lysis syndrome in T-cell malignancy: two case reports. 2019 , 6, 24	3
352	Tumor Lysis Syndrome. 2019 , 1421-1435	
351	Intraoperative tumor lysis syndrome in a giant teratoma: a case report. 2019 , 19, 62	2

350	Intracranial Hemorrhage in Childhood Acute Leukemia: Incidence, Characteristics, and Contributing Factors. 2019 , 99, 23-30	2
349	Ibrutinib and Venetoclax for First-Line Treatment of CLL. 2019 , 380, 2095-2103	256
348	Spontaneous Tumor Lysis Syndrome Secondary to Small-Cell Neuroendocrine Carcinoma of Unknown Origin: A Rare Case Report and Literature Review. 2019 , 2019, 6375693	5
347	Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol. 2019 , 9, e026644	16
346	Tumour lysis syndrome. 2019 , 152, 397-404	2
345	Tumour lysis syndrome in a patient with undifferentiated endometrial stromal sarcoma. 2019 , 28, 41-43	2
344	AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. 2019 , 37, 1188-1199	165
343	Febuxostat administration for the prevention of tumour lysis syndrome: A meta-analysis. 2019 , 44, 525-533	8
342	Review of oncological emergencies in small animal patients. 2019 , 5, 271-296	1
341	Update on the prevention and treatment of tumor lysis syndrome. 2019 , 3, 19-30	1
340	Diagnosis and Treatment-Related Complications of Acute Leukemia. 2019 , 9-28	
339	Acute Kidney Injury in Oncology and Tumor Lysis Syndrome. 2019 , 234-250.e1	1
338	Acute kidney injury in the patient with cancer. 2019 , 38, 295-308	28
337	Acute Liver Failure as the Leading Manifestation of Spontaneous Tumour Lysis Syndrome in a Patient with NonHodgkin Lymphoma: Do Current Diagnostic Criteria of Tumour Lysis Syndrome Need Re-Evaluation?. 2019 , 2019, 2358562	
336	Tumor lysis syndrome in gynecologic cancers: An uncommon but important diagnosis to recognize. 2019 , 30, 100514	2
335	Impact Of ELN Risk Stratification, Induction Chemotherapy Regimens And Hematopoietic Stem Cell Transplantation On Outcomes In Hyperleukocytic Acute Myeloid Leukemia With Initial White Blood Cell Count More Than 100 10/L. 2019 , 11, 9495-9503	7
334	Carfilzomib-induced tumor lysis syndrome in relapsed multiple myeloma: a report of two cases. 2019 , 105, NP24-NP27	3
333	A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer. 2019 , 9, 354-369	60

332	Tumour lysis syndrome. 2019 , 152, 397-404	7
331	Tumor Lysis Syndrome: A Rare but Serious Complication of Radioligand Therapies. 2019 , 60, 752-755	11
330	Elements Associated With Early Mortality in Children With B Cell Acute Lymphoblastic Leukemia in Chiapas, Mexico: A Case-control Study. 2019 , 41, 1-6	O
329	Huge Hepatocellular Carcinoma Treated with Radical Hepatectomy after Drug-eluting Bead Transarterial Chemoembolization. 2019 , 58, 1103-1110	2
328	Tumor Lysis Syndrome. 2019 , 143, 386-393	24
327	Colorectal Cancer-Associated Spontaneous Tumor Lysis Syndrome: a Case Report and Review of the Current Literature. 2019 , 50, 668-673	5
326	Oncologic Emergencies-The Old, the New, and the Deadly. 2020 , 35, 3-13	10
325	Utilization patterns and clinical outcomes of rasburicase administration according to tumor risk stratification. 2020 , 26, 529-535	2
324	Acute leukemias. 2020 , 540-554	
323	Notfle unter medikamentser Tumortherapie. 2020 , 26, 120-128	
322	Venetoclax-induced tumour lysis syndrome in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2020 , 188, 173-177	5
321	Real-world experience managing blinatumomab toxicities in adults with relapsed/refractory acute lymphoblastic leukemia. 2020 , 26, 1080-1085	1
320	An upsurge of the serum free light chains as a possible missing link in tumour lysis syndrome in multiple myeloma. <i>British Journal of Haematology</i> , 2020 , 188, 732-735	3
319	Tumor Lysis Syndrome. 2020 , 41, 20-26	5
318	Rare case presentation: DLBCL and plasma cell myeloma coexisting together. 2020 , 29, 587-590	
247		
317	Tumor lysis syndrome. 2020 , 275-280.e3	
316	Tumor lysis syndrome. 2020 , 275-280.e3 Calcium and phosphorus disorders. 2020 , 29-44.e5	1

314	Minimizing and managing treatment-associated complications in patients with chronic lymphocytic leukemia. 2020 , 13, 39-53	5
313	Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R) vs. rituximab + placebo in relapsed/refractory indolent non-Hodgkin lymphoma. 2020 , 111, 409-416	3
312	Evaluation of the safety and efficacy of low-dose rasburicase in critically ill children with haematological malignancies. 2020 , 42, 1440-1446	1
311	Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments?. 2020 , 9,	7
310	Safety of venetoclax rapid dose escalation in CLL patients previously treated with B-cell receptor signaling antagonists. 2020 , 4, 4860-4863	8
309	Oncological Emergencies from Pathophysiology and Diagnosis to Treatment: A Narrative Review. 2020 , 35, 689-709	9
308	Fatal Spontaneous Tumor Lysis Syndrome in a Patient with Metastatic Colon Cancer: A Clinical Case of Rare Oncological Emergency. 2020 , 14, 255-260	1
307	Palliative cytoreduction with low-dose intravenous melphalan in patients with acute myeloid leukemia refractory to prior treatment. 2020 , 1-6	O
306	Diagnosis and management of tumor lysis syndrome. 2020 , 10, 269-272	4
305	Bortezomib administration is a risk factor associated with the development of tumor lysis syndrome in male patients with multiple myeloma: a retrospective study. 2020 , 20, 1117	1
304	Pediatric onco-nephrology: time to spread the word: Part I: early kidney involvement in children with malignancy. 2021 , 36, 2227-2255	1
303	KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation. 2020 , 98, 1407-1418	3
302	Spontaneous clinical tumor lysis syndrome in solid renal tumor: first case report in non-metastatic renal carcinoma. 2020 , 4, 124-127	
301	Spontaneous Tumor Lysis Syndrome in Blastoid-Variant Mantle Cell Lymphoma: Considerations for the General Internist. 2020 , 8, 2324709620944709	O
300	Tumor lysis syndrome: still the Achilles heel of venetoclax in treatment of CLL?. 2020, 61, 2286-2288	2
299	Assessment of rasburicase utilization for tumor lysis syndrome management in pediatric and adult patients in the inpatient and outpatient settings. 2021 , 27, 1165-1171	O
298	Tumor lysis syndrome associated with nivolumab plus ipilimumab combination therapy in a melanoma patient. 2020 , 47, e411-e412	3
297	A new childhood ALL case with an extremely complex karyotype and acute spontaneous tumor lysis syndrome. 2020 , 13, 44	

296	Laboratory features of tumour lysis syndrome following daratumumab monotherapy in relapsed/refractory multiple myeloma. 2020 , 1, 312-314	
295	Type B lactic acidosis due to Warburg effect in a child presenting with T cell acute lymphoblastic leukaemia: a milder phenotype. 2020 , 13,	
294	Protein energy-wasting associated with nephrotic syndrome - the comparison of metabolic pattern in severe nephrosis to different stages of chronic kidney disease. 2020 , 21, 346	1
293	Case 38-2020: A 52-Year-Old Man with Cancer and Acute Hypoxemia. 2020 , 383, 2372-2383	1
292	Perspectives From an Onconephrology Interest Group: Conference Report. 2020 , 7, 2054358120962589	
291	Ixazomib-associated tumor lysis syndrome in multiple myeloma: A case report. 2020 , 99, e22632	1
290	A survey of hypercalciuria during chemotherapy in acute lymphoblastic leukemia. 2021 , 63, 923-928	1
289	Biomarkers in individualized management of chimeric antigen receptor T cell therapy. 2020 , 8, 13	13
288	Tumor lysis syndrome as a risk factor for very early mortality in HIV-associated non-Hodgkin's lymphoma: A 10-year single-center experience. 2020 , 83, 371-376	O
287	Acquired pyroglutamic acidosis due to long-term dicloxacillin and paracetamol use. 2020, 13,	4
286	Nursing in patients with hematological malignancies. 2020 , 9, IJH24	1
285	Treatment Outcome in Pediatric Acute Lymphoblastic Leukemia With Hyperleukocytosis in the Yeungnam Region of Korea: A Multicenter Retrospective Study. 2020 , 42, 275-280	3
284	Tumor Lysis Syndrome in a Patient With Gastric Adenocarcinoma. 2020 , 8, 2324709620933427	2
283	Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS/VOD after haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2020 , 190, 822-836 $^{4.5}$	21
282	Acute kidney injury with extreme hyperuricemia after antithymocyte globulin treatment in a kidney transplant recipient with underlying aplastic anemia: a case report. 2020 , 21, 251	2
281	Venetoclax plus cytochrome P450 inhibitors without ramp-up strategy led to low risk of tumor lysis syndrome in acute myeloid leukemia. 2020 , 99, 2193-2195	1
280	Pembrolizumab-axitinib-induced tumor lysis syndrome in a patient with metastatic renal cancer. 2020 , 8, 704-708	3
279	Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations. 2020 , 7, e168-e176	4

278	Management of Mantle Cell Lymphoma in the Era of Novel Oral Agents. 2020, 54, 879-898	2
277	Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia. 2020 , 89, 106298	9
276	Pazopanib after Nivolumab-Induced Tumor Lysis Syndrome in a Patient with Metastatic Clear-Cell Renal Cell Carcinoma. 2020 , 13, 249-254	2
275	Risk of tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax-containing regimens without dose ramp-up. 2021 , 100, 595-599	2
274	Incidence of tumor lysis syndrome in patients with acute myeloid leukemia undergoing low-intensity induction with venetoclax. 2021 , 96, E65-E68	4
273	High dose cyclophosphamide for cytoreduction in patients with acute myeloid leukemia with hyperleukocytosis or leukostasis. 2021 , 62, 1195-1202	1
272	Spontaneous Tumor Lysis Syndrome. 2020 , 13, 1116-1124	4
271	Efficacy of Single Low-Dose Rasburicase in Management of Tumor Lysis Syndrome in Leukemia and Lymphoma Patients. 2021 , 21, e99-e104	1
270	Oncologic Emergencies: Traditional and Contemporary. 2021 , 37, 85-103	3
269	Onconephrology: The intersections between the kidney and cancer. 2021 , 71, 47-77	27
269 268	Onconephrology: The intersections between the kidney and cancer. 2021 , 71, 47-77 Tumor lysis Syndrome in a Patient with Metastatic Breast Cancer Treated with Alpelisib. 2021 , 15, 117822	
268	Tumor lysis Syndrome in a Patient with Metastatic Breast Cancer Treated with Alpelisib. 2021 , 15, 117822	
268	Tumor lysis Syndrome in a Patient with Metastatic Breast Cancer Treated with Alpelisib. 2021, 15, 117822 Anesthesia for Pediatric Cancers. 2021, 335-354 Excessive elevation of serum phosphate during tumor lysis syndrome: Lessons from a particularly	
268 267 266	Tumor lysis Syndrome in a Patient with Metastatic Breast Cancer Treated with Alpelisib. 2021, 15, 117822 Anesthesia for Pediatric Cancers. 2021, 335-354 Excessive elevation of serum phosphate during tumor lysis syndrome: Lessons from a particularly challenging case. 2021, 9, 39-44 Urate Nephropathy from Tumor Lysis Syndrome in an Undiagnosed Case of Prostate Cancer. 2021,	
268 267 266 265	Tumor lysis Syndrome in a Patient with Metastatic Breast Cancer Treated with Alpelisib. 2021, 15, 117822 Anesthesia for Pediatric Cancers. 2021, 335-354 Excessive elevation of serum phosphate during tumor lysis syndrome: Lessons from a particularly challenging case. 2021, 9, 39-44 Urate Nephropathy from Tumor Lysis Syndrome in an Undiagnosed Case of Prostate Cancer. 2021, 28, 440-444	34211037421
268 267 266 265 264	Tumor lysis Syndrome in a Patient with Metastatic Breast Cancer Treated with Alpelisib. 2021, 15, 117822 Anesthesia for Pediatric Cancers. 2021, 335-354 Excessive elevation of serum phosphate during tumor lysis syndrome: Lessons from a particularly challenging case. 2021, 9, 39-44 Urate Nephropathy from Tumor Lysis Syndrome in an Undiagnosed Case of Prostate Cancer. 2021, 28, 440-444 Prognostic Factors in AML. 2021, 127-175 Immune Dysfunction in Patients with Chronic Lymphocytic Leukemia and Challenges during	1

260	Oncological Critical Care Considerations in Children. 2021 , 1167-1205	1
259	Endocrinology and Metabolism. 2021 , 377-395	1
258	Spontaneous tumour lysis syndrome in multiple myeloma with loss of 17p13.1, t(4;14) and monosomy 13. 2021 , 14,	0
257	The Effective Control of Hyperuricemia in Cancer Patients: A New Recombinant Conjugated Variant of Urate Oxidase. 2021 , 22, 627-632	1
256	Advanced Practice Perspectives on Preventing and Managing Tumor Lysis Syndrome and Neutropenia in Chronic Lymphocytic Leukemia. 2021 , 12, 59-70	
255	Process development of recombinant Aspergillus flavus urate oxidase production in Pichia pastoris intracellularly and its characterization as a potential biosimilar. 2021 , 102, 376-385	0
254	Kidney injury and disease in patients with haematological malignancies. 2021 , 17, 386-401	2
253	Acute Kidney Injury in the Patient with Cancer. 2021 , 11,	1
252	Can conventional clinical chemistry tests help doctors in the monitoring of oncology patients?. 2021 , 10,	
251	Tīhā Lizis Sendromunda Hemfrelik Yakla∰ ⊞	
250	Rasburicase-induced haemolysis and methemoglobinemia: an ongoing issue. 2021, 14,	1
249	Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups. 2021 , 56, 1888-1899	7
248	Tumor Lysis Syndrome: Implications for Oncology Nursing Practice. 2021 , 37, 151136	1
247	Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma. 2021 , 10, 3214-3223	9
246	Clinical characteristics of tumor lysis syndrome in childhood acute lymphoblastic leukemia. 2021 , 11, 9656	0
245	Tumor lysis syndrome induced by BRAF/MEK double blockade in a patient with metastatic melanoma: A first case report. 2021 , 48, e324-e326	3
244	Management of Hyperleukocytosis in Childhood Acute Leukemia Without Leukapheresis and Rasburicase Prophylaxis. 2021 ,	1
243	Epidemiology and prognosis of patients with a history of cancer admitted to intensive care. A multicenter observational study. 2021 , 45, 332-346	

242	Things We Do for No ReasonERasburicase for Adult Patients With Tumor Lysis Syndrome. 2021 , 16, 424-427	0
241	Follow-Up Study on Management of Tumour Lysis Syndrome with Single Low Fixed Dose (1.5 mg) of Rasburicase - A Tertiary Cancer Centre Experience from India. 2021 , 8, 2149-2154	
240	A Rare Case of Spontaneous Tumor Lysis Syndrome in Hodgkin Lymphoma. 2021 , 13, e15887	
239	Therapeutics for paediatric oncological emergencies. 2021 , 10,	1
238	Spontaneous Tumour Lysis Syndrome Secondary to Metastatic Gallbladder Adenocarcinoma: a Case Report and Reflection. 1	
237	Fluid overload and acute kidney injury in children with tumor lysis syndrome. 2021 , 68, e29255	1
236	Experience in the successful application of extracorporeal methods in treatment of tumor lysis syndrome. 2021 , 20, 106-110	
235	Impact of Oncology Pharmacists on the Knowledge, Attitude, and Practices of Clinicians to Enhance Patient Engagement of Self-Administered Oral Oncolytics. 2021 , 9,	
234	Single-Dose Rasburicase Might Be Adequate To Overcome Tumor Lysis Syndrome In Hematological Malignancies. 2021 ,	O
233	Tumor lysis syndrome in advanced and high-grade endometrial cancers: A case report and review of the literature. 2021 , 37, 100761	o
232	Management of Myeloma Manifestations and Complications: The Cornerstone of Supportive Care: Recommendation of the Canadian Myeloma Research Group (formerly Myeloma Canada Research Network) Consensus Guideline Consortium. 2021 ,	O
231	First case report of tumor lysis syndrome and acute renal failure after selinexor use in multiple myeloma. 2021 , 1-4	O
230	Epidemiologi y pronitico de los pacientes con antecedentes de neoplasia ingresados en las Unidades de Cuidados Intensivos. Estudio multiclitrico observacional. 2021 , 45, 332-346	
229	A phase 2 trial of single low doses of rasburicase for treatment of hyperuricemia in adult patients with acute leukemia. 2021 , 107, 106588	2
228	Immune Checkpoint Inhibitor-Associated Tumor Lysis Syndrome: A Real-World Pharmacovigilance Study. 2021 , 12, 679207	
227	Tumor Lysis Syndrome in a Low-Risk Pancreatic Cancer Patient. 2021 , 14, 1310-1314	1
226	Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy. 2021 , 5, 4465-4475	3
225	Oncologic Emergencies. 2021 , 32, 306-314	2

224	Tumor Lysis Syndrome in a Patient With Metastatic Endometrial Cancer Treated With Lattice Stereotactic Body Radiation Therapy. 2022 , 7, 100797	0
223	Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. 2021 , 22, 1391-1402	18
222	Literatur. 2021 , 653-661	
221	Fatal tumor lysis syndrome in a patient with metastatic gastric adenocarcinoma. 2021 , 11, e2020225	
220	Managing tumor lysis syndrome. 2021 , 34, 10-13	2
219	Tumour Lysis Syndrome in Occult Breast Cancer Treated With Letrozole - A Rare Occurrence. A Case Report and Review. 2021 , 15, 11782234211006677	1
218	A Rare Side Effect of Ibrutinib: Tumor Lysis Syndrome. 2021 , 36, 176-179	0
217	Endocrine and Metabolic Symptoms of Cancer and Its Treatment. 2010 , 117-124	2
216	Endocrine and Metabolic Emergencies. 2016 , 243-262	6
215	Arrhythmias and Electrolyte Imbalances as Consequences of Cancer. 2017, 75-88	2
214	Acute Tumor Lysis Syndrome: Diagnosis and Management. 2009 , 819-827	3
213	Acute Lymphoblastic Leukemia. 2009 , 295-330	2
212	Malignant Lymphomas and Lymphadenopathies. 2009 , 417-505	4
211	Acute Kidney Injury. 2012 , 1044-1099	10
210	[Unusual Cause of Acute Kidney Failure in a Patient with Metastatic Bladder Carcinoma Undergoing Palliative Chemotherapy]. 2020 , 109, 1070-1073	0
209	Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice. 2020 , 61, 2383-2388	11
208	Case report: acute tumour lysis syndrome following encorafenib and binimetinib for v600E metastatic melanoma with large intra-abdominal mass. 2020 , 30, 625-627	4
207	Tumour lysis in newborn: spontaneous or secondary to antenatal steroids?. 2018 , 2018,	3

206	Spontaneous tumour lysis syndrome in small cell lung cancer: a rare phenomenon. 2018, 2018,	5
205	Prevention and Treatment of Tumor Lysis Syndrome in the Era of Onco-Nephrology Progress. 2020 , 45, 645-660	7
204	Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma. 2020 , 136, 2628-2637	16
203	A 78-year-old man with acute myeloid leukemia (AML) and acute renal failure. 2014 , 15, 364-7	4
202	A Rare Case of Spontaneous Tumor Lysis Syndrome in Idiopathic Primary Myelofibrosis. 2019 , 20, 146-150	3
201	A Case Report of Atezolizumab Induced Tumor Lysis Syndrome. 2019 , 20, 785-789	6
200	Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia: A Rare Case Report from Nephrology. 2019 , 20, 1776-1780	O
199	Tumor Lysis Syndrome After a Single Dose of Atezolizumab with Nab-Paclitaxel: A Case Report and Review of Literature. 2020 , 21, e925248	2
198	Tumor lysis syndrome in pediatric acute lymphoblastic leukemia at tertiary care center. 2019 , 35, 899-904	3
197	Tumor lysis syndrome following sorafenib treatment in hepatocellular carcinoma. 2015 , 32, 47	2
196	Outcomes in Critically Ill Patients with Cancer-Related Complications. 2016, 11, e0164537	20
195	Incidence of and risk factors for newly diagnosed hyperkalemia after hospital discharge in non-dialysis-dependent CKD patients treated with RAS inhibitors. 2017 , 12, e0184402	8
194	Pediatric mature B-cell non Hodgkin lymphoma treatment with LMB-96 protocol. The Children Cancer Hospital Egypt experience. 2015 , 3, 3215	1
193	Spontaneous Tumor Lysis Syndrome in Small-Cell Lung Cancer: A Rare Complication. 2015 , 6, 464-471	7
192	A Case of Spontaneous Tumor Lysis Syndrome in Malignant Melanoma. 2016 , 7, 40-44	10
191	A Case Report of Inflammatory Syndrome Presenting as Tumor Lysis Syndrome after Single Dose of Nivolumab. 2017 , 8,	1
190	Systemic inflammatory response syndrome and multiple organ dysfunction in patients with acute tumor lysis syndrome. 2009 , 64, 479-81	35
189	Successful treatment of acute tumor lysis syndrome associated with transcatheter chemoembolization with large hepatocellular carcinomas: two case reports 2020 , 9, 6516-6521	1

188	Low-dose steroid-induced tumor lysis syndrome in a hepatocellular carcinoma patient. 2015 , 21, 85-8	11
187	Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient. 2009 , 15, 4464-6	40
186	Tumor lysis syndrome after transarterial chemoembolization of hepatocellular carcinoma: case reports and literature review. 2009 , 15, 4726-8	42
185	Spontaneous tumor lysis syndrome in a patient with cholangiocarcinoma. 2014 , 5, E46-9	14
184	Spontaneous Tumor Lysis Syndrome in Metastatic Melanoma. 2011 , 2, 204-207	7
183	Preventing acute renal failure is crucial during acute tumor lysis syndrome. 2007 , 11, 29-35	2
182	A Case Report of Newly Diagnosed Epithelial Ovarian Carcinoma Presenting with Spontaneous Tumor Lysis Syndrome and Its Successful Management with Rasburicase. 2017 , 38, 360-362	4
181	Hematological malignancies presenting as spontaneous tumor lysis syndrome: A case series. 2018 , 7, 1116-1119	4
180	Chemotherapy-Induced Tumour Lysis Syndrome in Gastric Adenocarcinoma with Diffuse Liver Metastases: A Case Report. 2018 , 09, 16-22	3
179	Radiation-Induced Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia. 2016 , 33, 248-50	7
178	A rare cause of tumour lysis syndrome and acute kidney injury. 2020 , 50, 35-38	1
177	A case of tumor lysis syndrome and acute renal failure associated with elotuzumab treatment in multiple myeloma. 2017 , 5, 78-81	6
176	Tumour lysis syndrome: implications for cancer therapy. 2012 , 13, 3555-60	12
175	Tumor lysis syndrome in childhood malignancies. 2020 , 9,	8
174	Spontaneous Tumor Lysis Syndrome in Small Cell Lung Cancer. 2017 , 9, e1017	9
173	Spontaneous Tumor Lysis Syndrome in an Adenocarcinoma of Unknown Origin. 2020 , 12, e12169	2
172	Spontaneous Tumor Lysis Syndrome in Diffuse Large B-cell Lymphoma: Early Diagnosis and Management. 2019 , 11, e4679	10
171	You Can't Always Blame the Chemo: A Rare Case of Spontaneous Tumor Lysis Syndrome in a Patient with Invasive Ductal Cell Carcinoma of the Breast. 2019 , 11, e6186	3

170	Spontaneous Tumor Lysis Syndrome Due to Endometrial Carcinoma. 2020 , 12, e7220	1
169	Tumor Lysis Syndrome in Solid Tumors: A Comprehensive Literature Review, New Insights, and Novel Strategies to Improve Outcomes. 2020 , 12, e8355	9
168	Hiding in (not so) plain sight: Spontaneous tumor Lysis syndrome due to intravascular large B cell lymphoma. 2021 ,	
167	Determinants of mortality in cancer patients with unscheduled admission to the Intensive Care Unit: A prospective multicenter study. 2021 ,	0
166	Tumor Lysis Syndrome in Lymphoblastic Crisis of CML. 2006 , 41, 119	
165	Oncologic Emergencies. 2007 , 767-773	
164	References. 2007 , 929-950	1
163	Tumor Lysis Syndrome. 2008 , 759-765	
162	Hematological and Oncological Emergencies. 2008, 781-801	
161	Disorders of Divalent Ion Metabolism. 2008 , 97-123	
160	Acute Tumor Lysis Syndrome: Diagnosis and Management. 2009 , 819-827	
159	Oncologic Emergencies. 2009, 1121-1143	
158	Haematological malignancies. 2009 , 1041-1048	
157	Stopping Acute Kidney Replacement Therapy. 2010 , 617-625	
156	The Generalized Care of the Patient with Acute Lymphoblastic Leukemia. 2011, 97-114	
155	Acute Kidney Injury in Cancer Patients. 2011 , 637-650	
154	Management of Emergencies in Leukemias. 373-391	
153	Tumor Lysis Syndrome. 2012 , 13-23	

152	Disorders of Calcium, Magnesium, and Phosphate Balance. 2012 , 689-725	3
151	Syndromes and Clinical Management Issues Associated with T-Cell Lymphomas. 2013 , 317-331	
150	Notfle in der Dermatoonkologie. 2014 , 209-218	
149	Critical Illness as a Result of Anti-Neoplastic Therapy. 2014 , 363-383	
148	Tumor Lysis Syndrome. 2014 , 591-596	
147	Severe Hyperphosphatemia Resulting in Acute Renal Failure and Ischemic Encephalopathy in a Patient with Infantile Leukemia. 2014 , 03, 129-134	
146	Successful prevention of tumor lysis syndrome using recombinant urate oxidase in patient with metastasic and bulky prostate rhabdomyosarcoma. 2014 , 03, 18-22	
145	Efficacy of Rasburicase on Hyperuricemia in Adult Patients with Malignant Tumor. 2014 , 31, 1110-1118	1
144	Metabolic Disturbance in Cancer Patients. 2015 , 737-752	
143	[Treatment in adult patients with acute myeloid leukemias and hyperleukocytosis at disease onset]. 2015 , 87, 33-40	
142	Clinical guidelines for the prevention and treatment of tumor lysis syndrome in children and adolescents. 2015 , 37-50	1
141	High Intensity Focused Ultrasound Treatment-Induced Tumor Lysis Syndrome in Uterine Myoma Patient. 2015 , 21, 99-101	O
140	Perioperative Care of Children with Cancer. 2016 , 229-258	1
139	Emergencies in Breast Cancer. 2017 , 697-708	
138	Tumor Lysis Syndrome. 2017 , 641-645	
137	Acute Leukemias. 2017,	
136	A child with bulky kidneys and renal failure. 2018 , 39, 388	
135	Endocrine and Metabolic Symptoms of Cancer and Its Treatment. 2018 , 233-246	

134	Tumor Lysis Syndrome. 2018 , 1-15	
133	A STUDY OF COMMON COMPLICATIONS IN ACUTE LEUKEMIA PATIENTS AT PEDIATRIC CENTER IN HUE CENTRAL HOSPITAL. 2018 , 8, 34-39	
132	LBffetWarburg, un challenge diagnostique pour le mBecin rBnimateur. 2019,	
131	Notfle in der Dermatoonkologie. 2019 , 275-284	
130	Tumor Lysis Syndrome in the Cancer Patient. 2019 , 1-15	
129	Metabolic Disturbance. 2019, 945-958	
128	Oncologic Emergencies in Pediatric Critical Care. 2019 , 1-20	
127	Tumor Lysis Syndrome in the Course of Burkitt Lymphoma Revealed by Medullar Compression. 2019 , 09, 429-435	
126	Brentuximab vedotin (Adcetris () in therapy of system anaplastic large cell lymphoma. Case report. 2019 , 13, 54-59	О
125	Assessment of tumor lysis syndrome cases.	
125	Assessment of tumor lysis syndrome cases. Oncologic emergencies. 2019, 65, 405-415	1
		1
124	Oncologic emergencies. 2019 , 65, 405-415 Dernifes avances the peutiques dans la prise en charge du syndrome de lyse tumorale. 2019 ,	1
124	Oncologic emergencies. 2019 , 65, 405-415 Dernifles avanclis the lapeutiques dans la prise en charge du syndrome de lyse tumorale. 2019 , 28, 287-289	1
124 123 122	Oncologic emergencies. 2019, 65, 405-415 Dernifles avancBs thfapeutiques dans la prise en charge du syndrome de lyse tumorale. 2019, 28, 287-289 Tumor Lysis Syndrome: Cancer Toxic Dump. 2020, 589-598 Comparative efficacy of chronic lymphocytic leukemia treatment with or without rituximab. 2019,	1
124 123 122	Oncologic emergencies. 2019, 65, 405-415 Dernifles avances the peutiques dans la prise en charge du syndrome de lyse tumorale. 2019, 28, 287-289 Tumor Lysis Syndrome: Cancer Toxic Dump. 2020, 589-598 Comparative efficacy of chronic lymphocytic leukemia treatment with or without rituximab. 2019, 14, 12-17	3
124 123 122 121 120	Oncologic emergencies. 2019, 65, 405-415 Dernifles avanclis the lapeutiques dans la prise en charge du syndrome de lyse tumorale. 2019, 28, 287-289 Tumor Lysis Syndrome: Cancer Toxic Dump. 2020, 589-598 Comparative efficacy of chronic lymphocytic leukemia treatment with or without rituximab. 2019, 14, 12-17 Tumor Lysis Syndrome. 2020, 611-614	

116	Slidrome de lisis tumoral. 2021 , 3,	
115	Tumor Lysis Syndrome in Patients With Hepatocellular Carcinoma: A Systematic Review of Published Case Reports. 2021 , 13, e19128	
114	Tumor lysis syndrome in chronic lymphocytic leukemia: conventional treatment versus novel agents: A protocol for systematic review and meta-analysis. 2020 , 99, e23632	О
113	Oncologic Emergencies in Pediatric Critical Care. 2020 , 1985-2004	
112	Tumor Lysis Syndrome in the Cancer Patient. 2020 , 1119-1133	1
111	SEIdrome de lisis tumoral. 2020 , 18, 177-184	
110	AKI in Setting of Cancer. 2020 , 111-124	
109	Oncologic Emergencies. 2020 , 477-501	O
108	A case of spontaneous tumor lysis syndrome in extensive-stage small-cell lung cancer: A rare oncologic emergency. 2020 , 20, 142-145	2
107	Tumorlysesyndrom: Prophylaxe und Therapie. 2005 , 237-239	
106	Emergencies in Acute Lymphoblastic Leukemia. 2008 , 281-288	
105	The Tumor Lysis Syndrome: An Oncologic and Metabolic Emergency. 2009 , 201-218	
104	Adult Burkitt Leukemia/Lymphoma. 2021 , 249-275	
103	A Needle in the Haystack: A Rare Case of Spontaneous Tumor Lysis in Newly Diagnosed Chronic Lymphocytic Leukemia Unmasked by Acute Renal Failure. 2020 , 12, e11279	O
102	Oncologic Emergencies. 2021 , 586-595	
101	Prevention and management of tumor lysis syndrome in adults with malignancy. 2013 , 4, 101-6	12
100	Clinical Interventions to Prevent Tumour Lysis Syndrome in Hematologic Malignancy: A Multisite Retrospective Chart Review. 2019 , 72, 435-445	2
99	Computational Approach for Rational Design of Fusion Uricase with PAS Sequences. 2020 , 9, 90-103	2

98	Acute Myeloid Leukemia: Advanced Practice Management From Presentation to Cure. 2020, 11, 836-844	1
97	Niere und Elektrolyte, Osteoprotektion. 2022 , 92-99	
96	Cytokine release syndrome and tumor lysis syndrome in a multiple myeloma patient treated with palliative radiotherapy: A case report and review of the literature. 2022 , 32, 24-28	0
95	Factors Affecting Short-Term Outcome of Critically Ill Children with Malignancies Admitted in Pediatric Intensive Care Unit: A Retrospective Observational Study. 2021 , 42, 333-338	
94	Tumor Lysis Syndrome in Breast Cancer 2021 , 29, e134-e137	1
93	Spontaneous tumor lysis syndrome and hemophagocytic lymphohistiocytosis in metastatic melanoma: A case series and review of the literature. 2021 , 7, 1	
92	Analysis of Short-Term Clinical Efficacy of Febuxostat in the Treatment of Malignant Tumor Complicated with Hyperuricemia. 2021 , 11, 5230-5236	
91	Onconephrology. 2021 , 1-30	
90	Venetoclax with Azacitidine Induced Tumor Lysis Syndrome in an Elderly Patient with Acute Myeloid Leukemia: A Case Report 2021 , 19, 46-50	1
89	Severe Hypocalcemia Due to Skeletal Remineralization After Venetoclax, Bortezomib, and Dexamethasone for Relapsed Multiple Myeloma 2022 , 10600280211062626	O
88	Acute Myeloid Leukemia: Advanced Practice Management From Presentation to Cure. 2020, 11, 836-844	1
87	Role of Pharmacogenomics in Reducing the Risk of Drug-Related latrogenesis. 2022 , 8, 79	O
86	Rasburicase induced methemoglobinemia: A systematic review of descriptive studies 2022 , 107815522210	75239
85	Serum phosphate level and its kinetic as an early marker of acute kidney injury in tumor lysis syndrome 2022 , 1	O
84	Hematology Emergencies in Critically Ill Adults: Malignant Hematology 2022,	
83	Spontaneous tumor lysis syndrome in adrenal adenocarcinoma: a case report and review of the literature 2022 , 16, 52	1
82	Pseudohyperkalemia accompanying actual hyperphosphatemia and hypocalcemia in an adolescent with T-lymphoblastic lymphoma 2021 , 101, 5-5	
81	International Society of Paediatric Surgical Oncology (IPSO) Surgical Practice Guidelines 2022 , 16, 1356	1

80	Tumor lysis syndrome, acute kidney injury and disease-free survival in critically ill patients requiring urgent chemotherapy 2022 , 12, 15	O
79	Evaluation of an interdisciplinary venetoclax initiation process in minimizing risk of tumor lysis syndrome 2022 , 1-8	
78	Hematologic and Oncologic Emergencies. 2022 , 132-162	
77	Onkologische Notfle im Behandlungsalltag. 2022 , 17, 78-90	
76	The Clinical Tumor Lysis Syndrome in a Patient with Mixed Phenotype Acute Leukemia Undergoing Induction with Venetoclax and Azacitidine - a Case Report 2022 ,	1
75	Retrospective Analysis of Pediatric Hepatoblastoma With Tumor Rupture: Experience From a Single Center 2022 , 10, 799307	
74	Acute kidney injury and childhood acute myeloid leukemia 2022, 1	
73	Acute Kidney Injury in Critically Ill Patients with Cancer 2022,	1
72	Tumor Lysis Syndrome 2021 , 28, 438-446.e1	1
71	Acute Kidney Injury in Patients With Cancer: A Review of Onconephrology 2021 , 28, 394-401.e1	O
70	Fatal Tumour Lysis Syndrome Induced by Brigatinib in a Lung Adenocarcinoma Patient Treated With Sequential ALK Inhibitors: A Case Report 2021 , 12, 809467	О
69	Tumor Lysis Syndrome Following Thoracotomy Under Cardiopulmonary Bypass in a Case of Hepatocellular Carcinoma With Right Atrial and Inferior Vena Cava Tumor Thrombus 2021 , 13, e20311	
68	Sfidrome de lisis tumoral espontfieo. 2020 , 5,	
67	A case report of tumor lysis syndrome after stage-one ALPPS 2022 , 101, e29040	
66	Review of Hematological and Oncological Emergencies 2022 , 44, 84-102	O
65	Tumor Lysis Syndrome in the Chronic Phase of Chronic Myeloid Leukemia Following COVID-19 Infection: A Case Report. 2022 ,	
64	Steroid-Induced Tumor Lysis Syndrome Accompanied by Diabetic Ketoacidosis and Acute Renal Failure in a Non-Hodgkin Lymphoma Patient. 2022 ,	
63	Tumor Lysis Syndrome and AKI: Beyond Crystal Mechanisms 2022,	1

62	Clinical considerations for DPD deficiency testing in advanced cancer patients: tumor lysis syndrome should be considered as a major interference 2022 ,	3
61	Tyrosine Kinase Inhibitors and Tumor Lysis Syndrome in Hematologic Malignancies: A Systemic Review 2022 ,	
60	Concomitant Kinase-Dead BRAF and Oncogenic KRAS Lead to an Aggressive Biologic Behavior and Tumor Lysis Syndrome: A Case Report 2022 , 12, 885814	
59	Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia 2022 , 117, 106844	О
58	Tumor Lysis Syndrome: An Endless Challenge in Onco-Nephrology. 2022 , 10, 1012	2
57	Prevention and Treatment of Acute Kidney Injury. 2022 , 197-226	
56	Transient abnormal myelopoiesis in Down syndrome: Experience of long term follow up from a single tertiary center in Thailand. 1-9	
55	Acute kidney injury following induction of chemotherapy: Diagnosis and management in critical care. 175114372211064	О
54	Oncologic emergencies and urgencies: A comprehensive review.	2
53	Spontaneous tumour lysis syndrome complicated by recurrent hypoglycaemia in first presentation of advanced lymphoproliferative disease.	
52	Tumour Lysis Syndrome. 2022 , 351-360	
51	Critical Care in Paediatric Tumours. 2022 , 361-372	
50	Spontaneous tumour lysis syndrome as a rare presentation of thymoma with peripheral blood lymphocytosis. 2022 , 31, 201010582210899	
49	Hematological Malignancies and the Kidney. 2022 , 29, 127-140.e1	
48	Sodium and Potassium Dysregulation in the Patient With Cancer. 2022, 29, 171-179.e1	
47	Tumor lysis syndrome following ifosfamide monotherapy in metastatic osteosarcoma: a case report and review of the literature. 2022 , 16,	О
46	Plasma cell leukemia presenting as spontaneous tumor lysis syndrome with hypercalcemia. 2022 , 10,	1
45	Post-remission outcomes in AML patients with high hyperleukocytosis and inaugural life-threatening complications. 2022 , 17, e0270744	

44	Spontaneous tumor lysis syndrome in a patient with accelerated phase chronic myeloid leukemia treated successfully with rasburicase. 2022 , 3, e0244	
43	Effectiveness and Safety of Allopurinol, Febuxostat, and Rasburicase in the Prevention of Tumor Lysis Syndrome: A Systematic Review and Network Meta-analysis.	
42	Adverse Renal Effects of Anticancer Immunotherapy: A Review. 2022 , 14, 4086	
41	Tumor lysis syndrome in pediatric patients with hematological malignancies. 2022 , 13, 118	O
40	Onconephrology. 2022 , 1445-1473	О
39	Tumor-Associated Renal Disease: New Challenges for Clinicians. 2022 , 12, 7135-7141	O
38	U.S. Food and Drug Administration Analysis of Newly Identified Adverse Events With Lurbinectedin: Extravasation, Rhabdomyolysis, and Tumor Lysis Syndrome. 2022 ,	О
37	Spontaneous Tumour Lysis Syndrome in Mantle Cell Lymphoma: A Case Study. 2022 ,	О
36	The multiple roles of LDH in cancer.	3
35	Tumor lysis syndrome. 2022 , 75, 157-160	O
34	Tumor Lysis Syndrome in Patients With Solid Tumors: A Systematic Review of Reported Cases. 2022	0
33	Massive hyperphosphatemia in clinical tumor lysis syndrome during prophylactic rasburicase use: risk factors and treatment options.	O
32	Oncologic Emergencies. 1-21	О
31	Mitigating acute chemotherapy-associated adverse events in patients with cancer. 2022 , 19, 681-697	O
30	Onco-Nephrology in the Critical Care Setting. 2022 , 34, 453-466	О
29	Utility of muscle ultrasound in nutritional assessment of children with nephrotic syndrome.	o
28	Leukoreductive response to the combination of sorafenib and chemotherapy in hyperleukocytosis of FLT3-ITD mutated pediatric AML. 10,	О
27	Miscellaneous Etiologies of Acute Kidney Injury. 2022 , 163-184	O

26	Cells Gone Wild: A Case Report on Missed Acute Leukemia and Subsequent Disseminated Intravascular Coagulation in the Emergency Department. 2022 , 6, 306-310	O
25	Repeated photodynamic therapy mediates the abscopal effect through multiple innate and adaptive immune responses with and without immune checkpoint therapy. 2022 , 121918	1
24	Oncologic Emergencies: Pathophysiology, Diagnosis, and Initial Management. 2022,	0
23	Determinants of mortality in cancer patients with unscheduled admission to the Intensive Care Unit: A prospective multicenter study. 2022 , 46, 669-679	O
22	Renal manifestations at initial diagnosis of childhood acute leukemias: a retrospective analysis from a single center. 2022 , 181,	0
21	PASylated Urate Oxidase Enzyme: Enhancing Biocatalytic Activity, Physicochemical Properties, and Plasma Half-Life. 2022 , 7, 46118-46130	O
20	Acute promyelocytic leukaemia: A central South African experience. 6,	0
19	A Retrospective Single-Center Study of Sevelamer Hydrochloride for the Treatment of Hyperphosphatemia in Children With Tumor Lysis Syndrome. 2023 ,	0
18	Review of Hematology-Oncology Emergencies for Internal Medicine Residents. 2023,	0
17	Clinical and economic burden of tumor lysis syndrome among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: A real-world US retrospective study. 2022 , 28, 1033-1045	O
16	Spontaneous Tumor Lysis Syndrome in an Undiagnosed Solid Organ Malignancy: Adenocarcinoma of the Colon. 2022 , 1, 86-88	O
15	Glomerulopathy in kidney neoplasms: frequency of occurrence, structure of morbidity. 2023 , 85, 21	O
14	Venetoclax ramp-up strategies for chronic lymphocytic leukaemia in the United Kingdom : a real world multicentre retrospective study.	0
13	Spontaneous Tumor Lysis Syndrome Secondary to Metastatic Small Cell Lung Cancer. 2023 ,	O
12	A case of disseminated intravascular coagulation following tumour lysis syndrome due to small cell carcinoma of the lung. 2023 , 11,	0
11	CE: Tumor Lysis Syndrome: An Oncologic Emergency. 2023 , 123, 30-35	O
10	Adverse drug events and contributing factors among pediatric cancer patients at Jimma University medical center, Southwest Ethiopia. 2023 , 23,	0
9	Burkitt lymphoma presenting as cecum mass and spontaneous tumor lysis syndrome with hypercalcemia. 2023 , 11,	O

CITATION REPORT

8	Tumor Lysis Syndrome Rare Presentation As Uremic Pericarditis: A Case Report. 2023,	O
7	Use of Prophylactic Drugs according to Risk Classification for TLS in Patients with Hematological Malignancies. 2023 , 40, 59-71	O
6	Oncologic Emergencies in Patients Undergoing Major Surgery. 2023 , 125-134	O
5	A phase II study to evaluate the efficacy of low-dose rasburicase (1.5mg) in adolescent and adult acute leukemia and high-grade lymphomas with tumor lysis syndrome. 2023 , 64, 628-638	O
4	Spontaneous Tumor Lysis Syndrome in a Patient With a Known History of Chronic Lymphocytic Leukemia Prior to Cytotoxic Chemotherapy. 2023 ,	O
3	Tumor lysis syndrome in hematological inpatients, experience from a university hospital in Brazil: A retrospective cohort study. 2023 ,	O
2	The effect of the time from diagnosis to induction therapy on prognosis in patients with acute leukemia undergoing leukapheresis for symptomatic hyperleukocytosis.	O
1	Malignancy diseases and kidneys: A nephrologist prospect and updated review. 2023 , 102, e33505	O